



2025 ANNUAL RESULTS

31 March 2026 2509.HK

Disclaimer

NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS

By attending this presentation or by reading this document, you (1) agree to be bound by these terms and (2) acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Group and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Group.

This document has been prepared regarding the company mentioned above in this document (the “Company”) and its subsidiaries (together, the “Group”) solely for use to introduce the Company and not for any other purpose, commercial, disclosure or otherwise.

This document contains proprietary information. The content of this document has not been independently verified. Certain factual statements and forecasts in this document are derived from external sources and have not been verified by the Company, any member of the Group (together, the “Relevant Parties”), any of their respective affiliates, or any controlling persons, directors, officers, employees, agents, advisors or representatives of any of the foregoing.

No express or implied representation, warranty or undertaking is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. None of the Company, members of the Group, the Relevant Parties, their respective affiliates, or the controlling persons, directors, officers, employees, agents, advisors or representatives of any of the foregoing shall have any liability (due to negligence or any other reasons) for any loss howsoever arising from any information contained or presented in this document or otherwise arising in connection with this document. The information contained herein, the accuracy of which is not guaranteed, is provided as at the date of this document and is subject to change without notice, and will not be updated or otherwise revised to reflect any developments which may occur after the date of this document.

This document contains forward-looking statements that reflect the Company’s current beliefs and expectations about the future as of the respective dates indicated herein. These statements contain the words “anticipate”, “believe”, “intend”, “estimate”, “expect” and words of similar meaning. All statements other than statements of historical facts included in this document, including, without limitation, those regarding the Chinese economy, the development trends of the relevant industry and the Company’s future financial position, results of operations, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Company’s products and services) are forward-looking statements. These forward-looking statements are based on a number of assumptions which are subject to known and unknown risks, uncertainties and other factors that are beyond the Company’s control, such as the political, social, legal and economic environment in which the Company will operate in the future, which could cause the actual results and performance of the Company to differ materially from the results and performance expressed or implied in such forward-looking statements. These forward-looking statements reflect the view of the Company’s management as of the date of this document only and are not a guarantee of future performance. Accordingly, no reliance should be placed excessively on these statements. None of the Company, members of the Group, the Relevant Parties, their respective affiliates, or the controlling persons, directors, officers, employees, agents, advisors or representatives of any of the foregoing assumes any obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that occur subsequent to such dates or otherwise, and each of the Company, members of the Group and Relevant Parties expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein.

This document and presentation contain information sourced from, and the views of, independent third parties. In replicating such information, none of the Company, members of the Group, the Relevant Parties, their respective affiliates, or any controlling persons, directors, officers, employees, agents, representatives or advisors of any of the foregoing makes any representation as to its accuracy or assumes any responsibility thereof. The replication of such views or information should not be treated as indication that the Company or the Relevant Parties agree or concur with such views or information.

This document and any oral information provided in connection with it do not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or any of its shareholders, subsidiaries or affiliates in any jurisdiction or an inducement to enter into investment activity. No money, securities or any other consideration is being solicited. No part of this document, nor the fact of its distribution, shall form the basis of or be relied upon in connection with any contract, commitment or investment decision whatsoever. No securities of the Company have been or will be registered under the U.S. Securities Act 1933, as amended (the “Securities Act”), and securities of the Company may not be offered or sold in the United States or to “U.S. persons” as defined in Regulation S under the Securities Act except pursuant to an exemption from, or in transactions not subject to, the registration requirements under the Securities Act. The information contained herein is not (a) an offering to you or the public of the shares or securities of the Company for purchase for cash or other consideration; or (b) circulated to invite offers by you or the public to purchase for cash or other consideration any securities of the Company.

You acknowledge and represent to the Company and its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisors that (1) you, and any person on whose behalf you are acting, are a “professional investor” as defined in the Securities and Futures Ordinance (Cap. 571) and the rules made thereunder, have the knowledge and experience in financial and business matters, and are capable of evaluating the merits and risks of and conducting your own assessment of the Company and its shares, (2) you, and any person on whose behalf you are acting, are a person into whose possession this document may lawfully be delivered in accordance with the laws of the jurisdiction in which you are located, (3) you, and any person on whose behalf you are acting, have and will conduct your own investigation with respect to the Group and have obtained or will obtain your own independent advice relating to the Group, and (4) you, and any person on whose behalf you are acting, are either (a) a “qualified institutional buyer” within the meaning of Rule 144A of the Securities Act”, or (b) outside the United States and not a U.S. person (as defined in Rule 902 of Regulation S under the Securities Act).

Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the company making the offer and that would contain detailed information about the company and management, as well as financial statements. There will be no public offering of the Company’s shares in the United States.

By attending this presentation or reading this document, you will be deemed to consent and agree that (i) you shall be bound by the restrictions as set forth in this document and to maintain absolute confidentiality regarding any information disclosed (whether written or verbal), and you shall indemnify and keep indemnified the Company, members of the Group, the Relevant Parties, their respective affiliates, and the controlling persons, directors, officers, employees, agents, advisors and representatives of each of the foregoing against all losses, damages, expenses and costs that any of them may sustain or incur as a result, whether directly or indirectly, of any breach of any provision in this disclaimer by you; (ii) any use of the information in this document by you other than in accordance with applicable law and stock exchange rules may constitute a violation of applicable laws, rules or regulations, including in relation to insider dealing/trading; and (iii) you are solely responsible for any consequences arising from any such violation. The distribution of the information in this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

Neither the delivery of this document nor any further discussions of the Company with any of the recipients of this document shall, under any circumstances, create any implication that there has been no change in the affairs of the Company or the Group since such date.

This disclaimer should be construed in accordance with the laws of Hong Kong.

Overview

01

2025 at A Glance: A Perfect Chain Reaction

02

A Stellar Global Debut with Rapid BsAbs Advance

03

Core MAbs Enter Harvest Phase with Strong Commercial Certainty

04

**A Significant Turnaround from Loss to Profit with
Improved Financial Position**

05

Outlook for 2026: A New Decade Sets Sail

Qyuns: Leveraging **Strong Comprehensive Capabilities** to Precisely Capture Growth Trends in China's Autoimmune Sector

A biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases



Exclusive Focus

Focus on **autoimmune and allergic disease therapies** since our inception



Full Coverage

Cover **four major disease areas** in the fields of Skin, Rheumatic, Respiratory and Digestive diseases




Huge Market Potential

Global market size of **US\$187.5 billion** in 2022 of autoimmune and allergic diseases, the **second-largest therapeutic area** globally



Comprehensive Pipeline

1 product approved
8 drug candidates
20+ IND approvals
Multiple ongoing clinical trials



Advanced Development Status

QX001S: 1st approved Ustekinumab biosimilar (SAILEXIN) in China
QX002N: for AS (**NDA accepted**)
QX005N: for AD, PN (**Phase III**)
QX004N: for Ps (**Phase III**)
QX008N: for COPD (**Phase III**)
Autoimmune bsAbs with leading progress globally



In-house Manufacturing

Established **commercial-scale**
Complies with U.S. and EU **cGMP**-standards
4 x 2,000L single-use bioreactors
~300 kg annual capacity



Strategic Partnership

Strategic partnerships with **Huadong Medicine, Joincare and Hansoh Pharma**
NewCo cooperation with **Atlas, LAV and venBio**
License agreements with **Roche and Windward**



Management Team

Experienced and diverse management team led by a successful serial entrepreneur and industry veteran

Exclusive Focus on Autoimmune and Allergic Disease Therapies, Covering Four Major Disease Areas and Key Therapeutic Pathways

mAbs bring commercial certainty; bsAbs boost efficacy and patient compliance



CRSwNP: chronic rhinosinusitis with nasal polyps
COPD: chronic obstructive pulmonary disease

Seasoned Management Team with Extensive Industry Experience and Successful Entrepreneurial Track Records



Jiwan Qiu

Executive Director, Chairman, General Manager

30 years of extensive R&D experience in biotechnology industry with deep knowledge and understanding of innovation

Various entrepreneurial achievements, founded and led several antibody-focused biotech companies

Previously founded Jiangsu T-mab, developed 4 therapeutic biologic drugs, including LA-GCSF, anti-VEGF mAb, Denosumab biosimilar, GLP-1 analogue

Genetics and genetic engineering, **Fudan University**



Yiliang Wu

Executive Director,
General Manager of Cellularforce



Weidong Lin

Executive Director,
Deputy General Manager



Shenglong Wu

Deputy General Manager



Xiao Liu, Ph.D.

Deputy General Manager



Cellularforce: Commercial Scale Production Capacity Supporting **Rapid CDMO Growth**

Commercial-scale in-house manufacturing capability that has received China's **GMP certification** and passed the **EU QP audit**

cGMP-standard manufacturing facility with excellent CMC capability and quality management will secure **high quality, cost controllable and reliable supply of products** for clinical study and commercialization

Manufacturing facility

- **4 x 2,000L** single-use bioreactors
- Approximately **300 kg annual capacity of therapeutic antibodies**




CMC capability and quality management


- **Strong CMC capability** to improve production efficiency
- **Excellent quality management** through QA and QC



An Integrated Strategic Alliance: Forged by Forward-Looking Layout and Seamless Integration of the Full Industry Chain, Spanning R&D, Production and Commercialization



Strategic Cooperation: Verify Pipeline Value, Generate Cash Income,
Accelerate Clinical Progress, Enhance Commercial Certainty



QX001S
August 2020
QX005N
July 2024



QX008N
January 2024



QX004N
April 2024



QX030N
April 2025



QX031N
October 2025



QX027N
December 2025

01

2025 at A Glance: A Perfect Chain Reaction

Qyuns in 2025: A Stellar Global Launch, Rapid BsAb Advance, MAbs Reaching Harvest Phase



Global expansion: NewCo and MNC deals

- Apr. 2025, NewCo deal with Caldera for QX030N, with a total amount of up to USD 555 million;
- Oct. 2025, Roche deal for QX031N, with a total amount of up to USD 1.07 billion;
- Dec. 2025, Windward deal for QX027N, with a total amount of up to USD 700 million.



Early stage BsAbs gradually form an innovative pipeline matrix

- To date, Qyuns has disclosed **4** innovative bsAbs, **3** of which have entered the clinical stage, **1** of those is scheduled to be submitted for IND;
- Leading position in bsAb R&D globally, driven by operational excellence.



SAILEXIN is maintaining a rapid growth momentum

- On Oct. 29, 2024, SAILEXIN, China's first Ustekinumab biosimilar, was approved with rapid nationwide sales launch;
- Sales in 2025 close to 300 RMB million.

1st Year of Profit Turnaround, Strengthening Future Capital Reserves




Revenue

RMB 800 million+



Adjusted Net Profit for the Year*

RMB 350 million+



Year-End Cash Balance*

RMB 1.04 Billion+

* Adjusted Net Profit for the year does not include the amortization of share-based compensation

* Cash balance includes cash and cash equivalents, time deposits, and financial assets at fair value through profit or loss

MAbs and BsAbs Portfolios Form the Foundation for a Comprehensive and Synergistic Pipeline

Drug		Target	Indication	Preclinical	IND Approval	Phase I	Phase II	Phase III	NDA Approval	Partners
	QX001S SAILEXIN	IL-12/ IL-23p40	Ps							华东医药 HUADONG MEDICINE
			CD							
	QX005N Oturkibart	IL-4Ra	PN							华东医药 HUADONG MEDICINE
			AD							
			CRSwNP							
			CSU							
			Asthma							
			COPD							
	QX002N Crusekitug	IL-17A	AS							
	QX004N	IL-23p19	Ps							翰森制药 HANSON PHARMA
			CD							
	QX008N	TSLP	COPD							健康元 Joincare
			Asthma							
	QX027N	TSLP/IL-13	Asthma+AD							Windward Bio
	QX030N	IL-23p19/TL1A	IBD							Caldera THERAPEUTICS
	QX031N	TSLP/IL-33	COPD+Asthma							Roche
	QX035N	c-kit/ undisclosed	Respiratory+Dermatology							

Dermatology
 Respiratory
 Gastroenterology
 Rheumatology

Marketed
 Under R&D
 Overseas Progress

02

A Stellar Global Debut with Rapid BsAbs Advance

QX027N (TSLP/IL-13) – Long-acting BsAb for Asthma and AD

\$ 700 million partnership with Windward Bio



- Subpicomolar affinity
- Long-acting modification
- Potential to advance standards beyond IL-4Rα-targeting mAbs
- Expected initiation of phase II clinical trial in H2 2026

Partner: **Windward Bio**

Latest Development: Phase I FPI in Dec. 2025 in China; Overseas IND to be submitted

Management Team Background:

- Led by experienced executives with strong R&D and commercial execution;
- >20 launches, raised ~\$1 billion, including two NASDAQ IPOs; two trade sales: Therachon to Pfizer in 2019 for up to \$810 million; VectivBio to Ironwood in 2023 for \$1.2 billion.

Financing Status: Series A financing: \$200 million (Jan. 2025)

orbimed

NOVO
holdings

 **BLUE OWL**

 **SR One**

 **OMEGA FUNDS**


rtw

QIMING
VENTURE PARTNERS

QUAN

P VOTAL
BIOVENTURE PARTNERS

Website: <https://windwardbio.com/>

QX030N (IL-23p19/TL1A) – Long-acting BsAb for IBD

\$ 555 million partnership with Caldera



- Potential next generation IBD treatment
- Improved efficacy, safety, and pharmacokinetics
- Potential to redefine the efficacy standard
- Leading R&D Progress

Partner:



Latest Development: Phase I FPI achieved in Australia in Jan. 2026

Management Team Background:

2024: Led the acquisition of Morpich Therapeutic by Lilly for \$3.2 billion, with its core asset being an $\alpha 4\beta 7$ small molecule inhibitor targeting the IBD field.

Financing Status: Series A financing: \$ 75 million (May 2025):



ATLAS VENTURE

LAV 礼来亚洲基金

venBio

Series A-1 Financing: \$ 37.5 million (Jan. 2026):



OMEGA FUNDS

WELLINGTON
MANAGEMENT®

Janus Henderson
INVESTORS

Website: <https://www.calderatx.com/>

QX031N (TSLP/IL-33) – Long-acting BsAb for COPD and Asthma

\$ 1.07 billion partnership with Roche



- Potential to be a “First-in-class” and “Best-in-disease” therapy
- Targets a broader patient population with COPD and Asthma
- Reshape the landscape of biologic therapy for respiratory diseases
- World-leading development progress

Latest Development: Phase I FPI achieved in New Zealand in Mar. 2026

Product Brief:

TSLP and IL-33 are proteins called alarmins that are released in the body in response to external factors such as allergens, viruses, pollution, and mechanical stimuli. They have been shown to be involved in respiratory diseases like COPD and asthma, and play important roles in the inflammatory processes.

QX031N is expected to be developed for the treatment of respiratory diseases.

QX035N – Next-Generation Long-acting c-kit BsAb for Respiratory and Dermatological Diseases

Next-generation allergy pipeline



- **First-in-class Product**
- **Designed to circumvent c-kit mechanism-related side effects**
- **Meet treatment needs for broader Patients with allergic diseases**
- **Expected IND submission in H2 2026**

QX035N is an investigational long-acting bsAb that **targets c-kit (a type III receptor tyrosine kinase) and an undisclosed second target.**

It is specifically designed to inhibit mast cell differentiation, maturation, survival, proliferation, and degranulation, thereby reducing and depleting mast cells for the treatment of mast cell-mediated diseases.

C-kit serves as the master regulator of mast cells, which are key drivers of inflammatory responses. However, current therapies are largely limited to blocking the mediators released by mast cells rather than targeting the source. Directly inhibiting mast cell activation and degranulation represents an innovative therapeutic approach for treating a range of allergic diseases.

Targeted Indications: CSU, AD, Asthma, AR, etc.



03

Core MAbs Enter Harvest Phase with Strong Commercial Certainty


SAILEXIN – 1st Ustekinumab Biosimilar Approved in China & Blockbuster Potential

Market Opportunities and Competition

Market Opportunities


In 2023, the number of psoriasis patients in China was estimated to be 7.2 million, among whom 60% had moderate-to-severe psoriasis

Ps drug market in China (USD Million)



Ustekinumab Global Sales

USD Million



Cooperation with Huadong Medicine



- In 2020, Zhongmei Huadong was granted the rights for joint development and exclusive commercialization of QX001S in **mainland China**
- We have received the upfront payment and milestone payments from Zhongmei Huadong, amounting to a total of RMB **50 million**
- After offsetting the attributable loss from the commercialization of QX001S, the parties will share the cumulative pre-tax profits from QX001S **on a 50:50 basis**
- The strategic partnership with Zhongmei Huadong will ensure **more efficient commercialization** of QX001S

Source: NMPA, CDE, Frost & Sullivan, prospectus of Dermavon

Competitive Advantages


The first marketed Ustekinumab Biosimilar in China (SAILEXIN)

- ✓ The commercial collaboration with Huadong Medicine has ensured rapid commercialization, **with 2025 sales close to RMB 300 million**
- ✓ Expect **better accessibility** than Stelara® (annual cost ~RMB16 thousand for maintenance treatment)

Ustekinumab: 10+ years clinical evidences on safety and efficacy

- ✓ **Higher drug survival rate: more effective** than TNF-α and IL-17 mAbs in long term
- ✓ **Convenient treatment regimen:** Q12W (QX001S) vs. Q4W (IL-17A mAb)
- ✓ In Phase III clinical trial for Ps, **QX001S demonstrated clinical equivalence to Ustekinumab** in terms of efficacy, safety, immunogenicity and PK profile

Clinical Development and Commercialization Process



Oct. 2024

Mar. 2025

H1 2026

Approval for Adult Ps

Approval for Pediatric Ps


Expected CD approval

Oturkibart (QX005N) – One of the Only Two IL-4Rα mAbs with **BT**D in China

Mechanism

- IL-4Rα controls the signaling of both IL-4 and IL-13, which is critical in the initiation of type 2 inflammation
- QX005N is designed to inhibit IL-4Rα, a well-validated, broad-acting target for a wide range of indications

2022 Prevalence of Covered Indications in China




Source: Frost & Sullivan, Sanofi annual reports



- In July 2024, the **exclusive joint development rights, exclusive commercialization options, and MAH transfer priority** were granted to Zhongmei Huadong in the designated area
- Zhongmei Huadong will **bear 50% of the Phase III clinical study costs** for the cooperative indications

Dupixent® Global Sales


USD Million



Oturkibart (QX005N) – Leading Progress in PN Development

Market Opportunities and Competition

Prevalence of PN in China, 2017-2030E



- Commonly associated with other skin diseases or underlying medical conditions that affect multiple body systems
- Biologic drugs have become a guideline treatment option for PN

Marketed Targeted Biologics for PN in China

Brand Name	INN	Company	Target	NMPA Approval Time
Dupixent®	Dupilumab	Sanofi	IL-4Rα	2023

Unmet Medical Needs

Limitation of current treatment

- Development of the PN drug market in China is still at an early stage
- Current treatment (topical steroids and topical anesthetics): only for **limited duration** due to **side effects**


Lack of effective treatment

- Lack of biologic drug: Dupixent® is the only treatment both approved by FDA and by NMPA for PN
- Dupixent® is the **only biologic drug approved for PN in China**

Urgent breakthrough needed

- **Jan. 2024 QX005N BTD received for PN**
- **Met primary endpoint in Phase III Clinical trial**

Clinical Development




Oturkibart (QX005N) – Treatment for Moderate-to-Severe AD, Covering Both Adolescent and Adult Patients

Market Opportunities and Competition

Market Opportunities


AD patients in China reached 70.3 million in 2022 and are anticipated to reach 78.5 million in 2030, 30% of which suffer from moderate-to-severe AD.

AD drug market in China (USD Million)



Sales Volume of Dupilumab in China

RMB Million



Source: Company data, Frost & Sullivan, Menet

Unmet Medical Needs

- **Systemic immunosuppressants** face significant safety concerns and inadequate efficacy in the long-term treatment of moderate-to-severe AD
- **Children above 6 months** demand absolutely safe and effective treatment of AD


Clinical Development and Commercialization

Commercialization

- > Key products in the dermatology portfolio
- > Expected to quickly realize its value through Huadong Medicine's channels

Phase III

- > Adolescent (12-17 yrs old) and adult patients are enrolled simultaneously
- > Met the primary endpoint in Phase III clinical trial




Crusekitug (QX002N) – IL-17A mAb for AS, with Clear Imaging Evidence

Market Opportunities and Competition

Market Opportunities

The AS patient population in China reached 3.9 million in 2022, mainly younger adults

AS drug market in China (USD Billion)



Unmet Medical Needs

- **40%** of AS patients intolerant to / inadequate disease control with **anti-TNF therapies**
- Guided as 2L standalone treatment for AS (the same designation as TNF inhibitors) for AS patients **with high disease activity after receiving first-line traditional treatments**

Competitive Advantages

IL-17A vs. TNF

- ✓ Guided as 2L standalone treatment for AS, IL-17A inhibitors have shown **clear clinical benefit** in patients who are intolerant to or fail to achieve adequate disease with TNF- α inhibitors
- ✓ IL-17A inhibitors are **more targeted** and with generally **fewer warnings and precautions**

Cost-effective in-house commercialization

Clinical Development

Phase III

- > Ph III data orally presented at the 2025 ACR Convergence
- > Clear objective imaging evidence

Promising data

- > At week 16, **ASAS40 40.4% vs 18.9%, ASAS20 65.2% vs 41.3%** (QX002N vs Placebo)
- > At week 52, **ASAS40 70.2%, ASAS20 87.2%**
- > Promising efficacy in TNF inhibitor-experienced patients, along with good safety profile

Feb. 2025

Mar. 2026

Ph III primary endpoint
data read-out

NDA accepted

QX004N – IL-23p19 mAb for Ps and CD, Top 2 Most Advanced Domestically


IL-23p19 is currently a better target for psoriasis, the treatment effect of psoriasis will be further improved, and it is conducive to long-term management.

Strategic cooperation with Hansoh Pharma



- On 24 April, 2024, Qyuns and Hansoh Pharma reached a strategic cooperation.
- Under the terms of the agreement, **Hansoh Pharma has paid an upfront payment of RMB 75.0 million**, and shall pay potential milestone payments of no more than RMB 1,032.0 million upon the achievement of development, regulatory and sales-based commercialization milestones, plus tiered royalties on future product sales.
- **Qyuns has received a total of RMB 143 million from Hansoh Pharma under the license agreement.**

Skyrizi® Global Sales



Clinical Development

Ps

- > Dec. 2024: Ph I data published in JAMA Dermatology
- > Mar. 2025: Hansoh presented Ph II data as a late-breaking oral presentation at the 2025 AAD Annual Meeting
- > **92.3% PASI 75 and 76.9% PASI 90** response rates in Phase II trial at 16 weeks (200mg dose)

CD

- > 2024.5 Ph Ia completed
- > Led by Hansoh subsequently

Aug. 2024

Q2 2025


Ph II primary endpoint data read-out for Ps

Ph III initiated

QX008N – TSLP mAb for Respiratory Diseases, Fastest COPD Progress in China

Tezspire® Global Sales

USD Million



- TSLP is a cytokine expressed by the airway epithelium and sits at the top of multiple inflammatory cascades
- Anti-TSLP mAb is the only biologic drug that is independent of eosinophilic levels and reduces the exacerbation of severe asthma in a broad population
- FDA granted Tezspire® BTM as an add-on maintenance therapy for moderate-to-very-severe COPD

Strategic Cooperation with Joincare




- In January 2024, we entered into a technology transfer agreement with Joincare to grant Joincare an exclusive license to develop, manufacture and commercialize QX008N in China, Hong Kong and Macau.
- Joincare will be responsible for the NDA application and will be the MAH of QX008N in the aforementioned area, once approved. We retain the exclusive rights to develop, manufacture and commercialize QX008N outside China, Hong Kong and Macau.
- Joincare achieved the FPI for Phase III clinical trial for COPD in March 2026, ranking the first among domestic players in China.

04

A Significant Turnaround from Loss to Profit with Improved Financial Position

Significant Operating Income Increase further Strengthened Capital Reserves




In 2025, Qyuns recorded a total revenue of **RMB 806.96 million, representing a 408.18% increase period-to-period.**

In 2025, the Company's revenue was mainly derived from upfront and milestone payments from licensing agreements, provision of R&D services, CDMO services and supply of SAILEXIN, showing robust growth.

(RMB Million)	2025	2024
Income	806.96	158.79

Turned to Profit for the First Time with Net Profit of RMB 300M+ and Adjusted Net Profit of RMB 350M+



In 2025, Qyuns recorded a **net profit of RMB 307.44 million**, a significant turnaround from a net loss of RMB 349.69 million in 2024, representing **an increase of RMB 657.13 million**. Meanwhile, its **adjusted net profit reached RMB 356.20 million**. The company achieved its first turnaround to profitability, further strengthening its capital reserves.


(RMB Million)	2025	2024
Net Profit/Loss	307.44	-349.69

Cash Reserves Strengthened with Optimized Loan Structure



Cash Reserves*

RMB Million



Strengthened Cash Reserves: As of December 31, 2025, Cash reserves amounted to **RMB 1,041.97 million**, an increase of RMB 485.84 million compared to RMB 556.13 million as of December 31, 2024, indicating sufficient cash reserves.


Sufficient credit lines and optimized loan structure: As of December 31, 2025, the unutilized credit facility available to the company amounted to **RMB 561.50 million**; as of December 31, 2025, the balance of working capital loan with terms of 2 to 3 years accounted for **92.03%** of the total working capital loan balance (December 31, 2024: 39.1%).

(RMB Million)	2025.12.31	2024.12.31
Cash reserves	1,041.97	556.13
Total non-current assets	483.66	367.15
Total current assets	1,116.67	616.73
Total non-current liabilities	417.49	332.67
Total current liabilities	503.74	430.16
Net current assets	612.93	186.56
Total equity	679.10	221.05

* Cash reserves include cash and cash equivalents, time deposits, and financial assets at fair value through profit or loss


Debt-to-Asset Ratio Declines as Debt Servicing Capacity Improves

Year-end Debt-to-Asset ratio 2024.12.31 – 2025.12.31



The debt-to-asset ratio of Qyuns declined from **77.5%** as of December 31, 2024, to **57.6%** as of December 31, 2025. This was primarily attributed to the substantial increase in cash and cash equivalents, time deposits. The increase was driven by the receipt of upfront and milestone payments from the licensing-out agreements for QX030N and QX031N, along with the net proceeds from the placement of new H shares.

(%)	2025.12.31	2024.12.31
Debt-to-Asset Ratio	57.6	77.5



05

Outlook for 2026: A New Decade Sets Sail

Outlook for 2026

1

Enhance Global Presence

Leveraging global partnerships to continuously expand overseas licensing deals and steadily build global clinical development capabilities

2

Strengthen the Foundation for Innovation

Accelerating the R&D of bsAbs and layout for next-generation frontier technologies



3

Ensure Registration Progress

Ensure the registration progress and secure the submission of key products

4

Improve Accessibility

Provide more patients access to high-quality and affordable treatment options by innovating and optimizing production

5

Consolidate Our Value Foundation

Continuously optimize the financial structure, strengthen cash flow management, and steadily improve operational quality and market value



IR@qyuns.net